|
| |
BioVexBioVex is a three year old private biotech company that is developing a new class of potent vaccines principally to treat and prevent cancer. The Company is headquartered in Oxford, UK.
The Company has three technology platforms based on the manipulation of the herpes simplex type one virus. The Company has two vaccine platforms; OncoVEX and ImmunoVEX and a functional genomics platform for gene determination in the nervous system (NeuroVEX)
The Company’s lead product OncoVEX GM-CSF is to enter Phase I/II studies in early 2002 in breast cancer, head and neck cancer and malignant melanoma. OncoVEX GM-CSF is scheduled to be the first lytic HSV vector (that selectively destroys tumour cells) containing an immune stimulating molecule to move into clinical development. It has the potential to treat metastatic as well as local disease.
The Company’s ImmunoVEX vaccine platform stimulates a key class of immune policing (dendritic) cells. The Company’s lead product to treat malignant melanoma is expected to enter the clinic in the first quarter of 2003.
The Company also has a portfolio of vaccines to treat other cancers and chronic infectious diseases for which pre-clinical data sets are being assembled. These include products for lung cancer, prostate cancer, HSV/HPV and Hepatitis B.
| Contact Details: |
| BioVex Ltd, 70 Milton Park, Abingdon |
| Oxon |
| Oxfordshire |
| OX14 4RX |
| United Kingdom |
| Tel: | +44 (0)1235 441900 |
| Fax: | +44 (0)1235 441901 |
| Email: | gbeynon@biovex.com |
| WWW: | www.biovex.com./
|
|
Loading...
|
Recent Publications by BioVex: |  |
Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor-Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma.
PURPOSE: Treatment options for metastatic melanoma are limited. We... | 4th November, 2009
| Mary Crowley Cancer Research Centers; Texas Oncology Physicians
| J Clin Oncol. 2009 Nov 2.
DOI Direct Link |
Retrograde viral transduction of cortical pyramidal neurons from the spinal cord.
PURPOSE: The primary motor pathway, the corticospinal tract, is a major... | 10th April, 2009
| Biovex Ltd, London, UK.
| Restor Neurol Neurosci. 2008;26(6):509-20.
|
Efficient delivery of RNA Interference to peripheral neurons in vivo using herpes simplex virus.
Considerable interest has been focused on inducing RNA interference (RNAi)... | 10th September, 2008
| BioVex Inc., 34 Commerce
| Nucleic Acids Res. 2008 Aug;36(14):e86. Epub 2008 Jun 25.
DOI Direct Link |
Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
BACKGROUND: Tumour necrosis factor alpha (TNFalpha) therapy is a promising... | 8th June, 2007
| Biovex Ltd., 70 Milton Park, Abingdon, Oxon OX14 4RX, UK.
| J Gene Med. 2007 Feb;9(2):99-106.
DOI Direct Link |
Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
We have previously developed an oncolytic herpes simplex virus-1 based on... | 6th July, 2006
| Biovex Inc., Woburn, Massachusetts 01801, USA.
| Cancer Res. 2006 May 1;66(9):4835-42.
DOI Direct Link |
→View more BioVex research publications. |
Press Releases on BioVex:
|
 |
| BioVex Completes $70 Million Financing to Conclude Pivotal Study With Its Pioneering Cancer Treatment, OncoVEX (GM-CSF) |
10th November, 2009 |
BioVex |
WOBURN, Mass., Nov. 10 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has
|
| BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology |
2nd November, 2009 |
BioVex Inc |
WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the data from
|
| BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting |
15th May, 2009 |
BioVex Inc |
WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that the results
|
| BioVex To Announce Updated Survival Data From a Phase II Clinical Study of OncoVEX GM-CSF in Metastatic Melanoma at The 2009 American Society of Clinical Oncology Meeting |
15th May, 2009 |
BioVex Inc |
WOBURN, Mass., May 15 /PRNewswire/ -- BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that updated survival
|
| BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma |
14th April, 2009 |
BioVex Inc |
WOBURN, Mass., April 14 /PRNewswire/ -- BioVex Inc, a company developing next generation biologics for the treatment and prevention of cancer and infectious disease, announced today that its OPTiM
|
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 884 times since April 2007, the link to the organisation's website has been followed 111 times Recent Search Terms used to find this page: immunovex 2009 hsv 2 | oncovex | neurovex 2009 | ImmunoVex-HSV 2 mutant | Biovex | biovex july 2009 | biovex patent | . Search for more companies in Oxon Search for more companies in Oxfordshire This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for BioVex |
